Abiraterone Approved for Earlier Use in Men with Metastatic Prostate Cancer

The Food and Drug Administration (FDA) has expanded the approval of abiraterone (Zytiga®) for men with prostate cancer. The agency approved abiraterone, in combination with the steroid prednisone, for men with metastatic prostate cancer that is responsive to hormone-blocking treatments (also known as castration-sensitive) and is at high risk of progressing.

from Cancer via ola Kala on Inoreader http://ift.tt/2Es22BT
via IFTTT